Source-linked reviews of peptide literature, analytical methods, study design, and research standards.
A source-linked review of 2026 Phase 3 survodutide data in obesity and fatty liver disease, including what the results suggest, where the evidence is strongest, and what still remains unresolved.
A clear explanation of bacterial endotoxin testing, sterility testing, why the two are separate, and what a passing result does—and does not—establish.
A practical evidence hierarchy for peptide research, from in-vitro studies and animal models through Phase 1, Phase 2, Phase 3, and regulatory review.
Why chromatographic purity and absolute peptide content are different measurements—and what a stronger analytical report should include.
A practical guide to what a peptide COA can establish, what it cannot, and how identity, purity, quantity, endotoxin, sterility, and method validation fit together.
A source-linked review of the peer-reviewed Phase 2 evidence, 2026 Phase 3 topline results, liver-fat findings, safety signals, and retatrutide’s current investigational status.